Open AccessA prospective case–control trial to evaluate and compare the efficacy and safety of atosiban versus placebo in In vitro Fertilization-embryo transfer program
Author(s) -
Vineet Mishra,
Himani Agarwal,
Sandeep Goel,
Priyankur Roy,
Sumesh Choudhary,
Sunita Lamba
Publication year - 2018
Publication title -
journal of human reproductive sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.484
H-Index - 31
eISSN - 0974-1208
pISSN - 1998-4766
DOI - 10.4103/jhrs.jhrs_7_17
Subject(s) - medicine , embryo transfer , pregnancy , obstetrics , in vitro fertilisation , placebo , pregnancy rate , gynecology , miscarriage , gestation , biology , alternative medicine , pathology , genetics
Recent developments in assisted reproductive technology focus on potential advances to improve its success rate. Atosiban, a combined oxytocin/vasopressin V1a receptor antagonist, is a novel class of drug involved in basic priming of the uterus for successful implantation during embryo transfer (ET).